Header Logo

Connection

KEVIN GAREY to Aged

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Aged.
KEVIN GAREY
Connection Strength
1.365
Aged
  1. Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 01 03; 6(1):e2253570.
    View in: PubMed
    Score: 0.054
  2. Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
    View in: PubMed
    Score: 0.049
  3. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
    View in: PubMed
    Score: 0.044
  4. Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clin Infect Dis. 2019 05 17; 68(11):1887-1893.
    View in: PubMed
    Score: 0.042
  5. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. J Glob Antimicrob Resist. 2018 12; 15:41-47.
    View in: PubMed
    Score: 0.039
  6. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.039
  7. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul; 93(3):286-9.
    View in: PubMed
    Score: 0.034
  8. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
    View in: PubMed
    Score: 0.032
  9. Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. Am J Health Syst Pharm. 2015 Jul 15; 72(14):1204-8.
    View in: PubMed
    Score: 0.032
  10. Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia. 2015 Feb; 179(1-2):87-93.
    View in: PubMed
    Score: 0.030
  11. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014; 9(7):e102848.
    View in: PubMed
    Score: 0.030
  12. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
    View in: PubMed
    Score: 0.030
  13. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun; 48(6):683-90.
    View in: PubMed
    Score: 0.029
  14. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep; 85(1):28-32.
    View in: PubMed
    Score: 0.028
  15. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr; 83(4):294-9.
    View in: PubMed
    Score: 0.027
  16. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
    View in: PubMed
    Score: 0.026
  17. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012 Apr; 343(4):277-80.
    View in: PubMed
    Score: 0.026
  18. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun; 56(6):3239-43.
    View in: PubMed
    Score: 0.026
  19. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb; 32(2):129-34.
    View in: PubMed
    Score: 0.025
  20. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul; 94(7):863-70.
    View in: PubMed
    Score: 0.024
  21. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep; 66(9):2146-51.
    View in: PubMed
    Score: 0.024
  22. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011 Sep; 79(1):23-6.
    View in: PubMed
    Score: 0.024
  23. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10.
    View in: PubMed
    Score: 0.023
  24. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010 Sep; 54(9):3717-22.
    View in: PubMed
    Score: 0.023
  25. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2009 Mar; 63(3):279-85.
    View in: PubMed
    Score: 0.020
  26. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009 Jan; 43(1):91-3.
    View in: PubMed
    Score: 0.020
  27. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.020
  28. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008 Dec; 70(4):298-304.
    View in: PubMed
    Score: 0.020
  29. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008 Oct; 70(2):142-7.
    View in: PubMed
    Score: 0.020
  30. Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. Pharmacotherapy. 2008 Jun; 28(6):699-706.
    View in: PubMed
    Score: 0.020
  31. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
    View in: PubMed
    Score: 0.019
  32. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008 Feb; 52(2):446-51.
    View in: PubMed
    Score: 0.019
  33. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007 Aug; 16(8):919-27.
    View in: PubMed
    Score: 0.019
  34. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
    View in: PubMed
    Score: 0.018
  35. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin. 2007 May; 23(5):1057-65.
    View in: PubMed
    Score: 0.018
  36. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents. 2007 May; 29(5):557-62.
    View in: PubMed
    Score: 0.018
  37. Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection. 2006 Dec; 34(6):322-7.
    View in: PubMed
    Score: 0.018
  38. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007 Jan; 51(1):35-9.
    View in: PubMed
    Score: 0.018
  39. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006 Aug; 28(8):1208-1216.
    View in: PubMed
    Score: 0.017
  40. Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8.
    View in: PubMed
    Score: 0.017
  41. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother. 2006 Sep; 58(3):645-50.
    View in: PubMed
    Score: 0.017
  42. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 01; 43(1):25-31.
    View in: PubMed
    Score: 0.017
  43. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006 May; 49(3):226-31.
    View in: PubMed
    Score: 0.017
  44. Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother. 2006 Mar; 40(3):381-5.
    View in: PubMed
    Score: 0.017
  45. Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals. Clin Infect Dis. 2026 Feb 09; 82(1):75-85.
    View in: PubMed
    Score: 0.017
  46. Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. Lancet Microbe. 2025 Aug; 6(8):101126.
    View in: PubMed
    Score: 0.016
  47. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
    View in: PubMed
    Score: 0.015
  48. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
    View in: PubMed
    Score: 0.015
  49. Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol. 2022 10; 43(10):1339-1344.
    View in: PubMed
    Score: 0.012
  50. Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes. 2021 Jan-Dec; 13(1):1-18.
    View in: PubMed
    Score: 0.012
  51. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000 Dec; 118(6):1826-7.
    View in: PubMed
    Score: 0.012
  52. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig Dis Sci. 2021 10; 66(10):3303-3306.
    View in: PubMed
    Score: 0.012
  53. Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms. J Clin Gastroenterol. 2018 08; 52(7):648-654.
    View in: PubMed
    Score: 0.010
  54. Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clin Microbiol Infect. 2018 Nov; 24(11):1190-1194.
    View in: PubMed
    Score: 0.010
  55. Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):754-758.
    View in: PubMed
    Score: 0.009
  56. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 09; 50(8):631-7.
    View in: PubMed
    Score: 0.009
  57. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
    View in: PubMed
    Score: 0.008
  58. Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. Epidemiol Infect. 2016 Jan; 144(1):189-97.
    View in: PubMed
    Score: 0.008
  59. A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One. 2015; 10(4):e0123405.
    View in: PubMed
    Score: 0.008
  60. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15; 60(6):892-9.
    View in: PubMed
    Score: 0.008
  61. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014 Jun; 35(6):667-73.
    View in: PubMed
    Score: 0.007
  62. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr; 21(4):509-17.
    View in: PubMed
    Score: 0.007
  63. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013 Jun; 57(6):2690-3.
    View in: PubMed
    Score: 0.007
  64. Clostridium difficile-related death rates in Texas 1999-2005. J Infect. 2009 Nov; 59(5):303-7.
    View in: PubMed
    Score: 0.005
  65. Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct; 31(5):565.
    View in: PubMed
    Score: 0.005
  66. Automated system to identify Clostridium difficile infection among hospitalised patients. J Hosp Infect. 2009 Aug; 72(4):337-41.
    View in: PubMed
    Score: 0.005
  67. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):964-8.
    View in: PubMed
    Score: 0.005
  68. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect. 2007 Jan; 65(1):42-6.
    View in: PubMed
    Score: 0.004
  69. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005 Apr; 27(2):81-2.
    View in: PubMed
    Score: 0.004
  70. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001 Sep; 21(9):1107-14.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.